8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 27, 2026·SEC
Material company update
Feb 24, 2026·SEC
Werewolf Therapeutics, Inc.(HOWL)Earnings, Financials & Key Ratios
HOWL•NASDAQ
$0.34
Price updated Jul 7, 2026
AboutWerewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$59M+17.7%
- Net Income-$61M+13.7%
- EPS (Diluted)-1.33+18.4%
- ROE-123.88%-62.3%
HOWL Price & Volume
Werewolf Therapeutics, Inc. (HOWL) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Costs Outpace Capital Reserves
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical Trial Funding Gap
Key Thesis Takeaways
- Werewolf Therapeutics remains a high-risk, pre-commercial biotechnology entity whose valuation is tethered to the success of its INDUKINE platform rather than current revenue generation.
- The company faces a narrowing operational runway, evidenced by a cash position that has declined to $58 million as of 2026Q1, necessitating potential dilutive financing to sustain ongoing R&D.
- Investors should monitor the company's ability to secure strategic partnerships, as the current trajectory of persistent quarterly operating losses exceeding $15 million threatens long-term solvency.
Verdict Logic
the company's rapid depletion of assets, which fell from $177.6 million in 2024Q1 to $58.0 million in 2026Q1, indicates a critical funding gap that poses a substantial risk to equity holders.
HOWL Growth Metrics
Werewolf Therapeutics, Inc. (HOWL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM22.3%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM26.22%
Return on Capital
10 Years-47.61%
5 Years-48.45%
3 Years-55.52%
Last Year-83.69%
Peers Comparison
Key metrics vs top competitors for Werewolf Therapeutics, Inc. (HOWL)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.34 | $16.72M | -0.26 | -100% | — | -123.88% | — | |
| $3.38 | $241.82M | -2.40 | — | — | -30.9% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $3.50 | $145.75M | -1029.41 | 10.37% | 52.16% | — | — | |
| $39.93 | $2.66B | -10.24 | -78.63% | -34596.22% | -50.72% | — | |
| $53.52 | $8.19B | 19.32 | 87.32% | 65.95% | 87.36% | — |
Compare HOWL vs Peers
Werewolf Therapeutics, Inc. (HOWL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HOWL SEC Filings & Documents
Werewolf Therapeutics, Inc. (HOWL) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when HOWL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
HOWL Frequently Asked Questions
Werewolf Therapeutics, Inc. (HOWL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is Werewolf Therapeutics, Inc. growing?
Werewolf Therapeutics, Inc. (HOWL) saw revenue decline by 100.0% over the past year.
Is HOWL profitable?
Werewolf Therapeutics, Inc. (HOWL) reported a net loss of $56.3M for fiscal year 2025.
Dividend & Returns
What is HOWL's return on equity?
Werewolf Therapeutics, Inc. (HOWL) has a return on equity (ROE) of -123.9%. Negative ROE indicates the company is unprofitable.
What is Werewolf Therapeutics, Inc.'s free cash flow?
Werewolf Therapeutics, Inc. (HOWL) had negative free cash flow of $51.9M in fiscal year 2025, likely due to heavy capital investments.